Core Viewpoint - Rosen Law Firm is encouraging investors of Telix Pharmaceuticals Ltd. to secure legal counsel before the January 9, 2026 deadline for a securities class action lawsuit related to the company's misleading statements during the class period from February 21, 2025, to August 28, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Telix securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 9, 2026 [3][6]. - The lawsuit alleges that Telix made materially false and misleading statements regarding its prostate cancer therapeutic candidates and the quality of its supply chain, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in achieving significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Skye Bioscience, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on January 16, 2026, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Skye securities between November 4, 2024, and October 3, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2]. - The lawsuit alleges that Skye's defendants made materially false and misleading statements regarding the effectiveness and prospects of nimacimab, leading to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in achieving significant settlements [3]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 in 2017 and consistently in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant stock price declines following the release of disappointing clinical trial results [1][3][4]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Skye to contact them for discussing legal options, with a deadline of January 16, 2026, to seek the role of lead plaintiff in a federal securities class action [1][5]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [2]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false and misleading statements about nimacimab's effectiveness and overstating its clinical, regulatory, and commercial prospects [3]. - On October 6, 2025, Skye announced that its nimacimab did not achieve the primary endpoint of weight loss compared to placebo, resulting in a 60% drop in stock price, closing at $1.90 per share [4].

Last time I took a look at Atara Biotherapeutics ( ATRA ), I was intrigued and optimistic about their allogeneic (non-self) CAR T-cell therapy, in a novel indication for engineered cell therapies. But that has been quiteI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfa ...

Core Insights - CRISPR Therapeutics has begun generating revenue from its first product, a blood disorder treatment called Casgevy, which has been approved by regulators [7][10] - Cathie Wood, CEO of Ark Invest, has been consistently increasing her holdings in CRISPR Therapeutics, indicating strong confidence in the company's future growth potential [5][6] - The stock has experienced significant declines, dropping 17% since the approval of Casgevy and over 55% in the past five years, presenting a potential buying opportunity for growth investors [12][13] Company Overview - CRISPR Therapeutics specializes in gene editing technology, which has shown promise in correcting faulty genes responsible for diseases [8] - The company has a market capitalization of $5 billion and its stock is currently priced at $53.47 [11] - CRISPR Therapeutics has a gross margin of -36522.94%, indicating challenges in profitability [11] Product and Revenue Generation - The approval of Casgevy is a significant milestone, demonstrating the effectiveness of CRISPR's technology and paving the way for future product approvals [7][8] - Vertex Pharmaceuticals, a partner of CRISPR, expects Casgevy to generate over $100 million in revenue this year, with CRISPR receiving 40% of the profits [10] - The rollout of gene editing treatments is complex and time-consuming, which means revenue generation will take time [10] Clinical Trials and Future Prospects - CRISPR Therapeutics is advancing other candidates through clinical trials, including CTX310, which has shown positive results in lowering triglycerides and LDL levels [11] - The company is exploring applications of its technology in various fields, including oncology and cardiovascular health [11] - Despite recent stock price declines, the approval of Casgevy and positive trial results suggest that CRISPR Therapeutics has significant growth potential ahead [12][13]

Core Viewpoint - The article emphasizes the focus on non-consensus long-short investment ideas within the biotechnology sector, particularly targeting small to mid-cap companies in the US and EU markets, with an interest in clinical catalysts and new drug launches [1]. Group 1: Investment Focus - The company specializes in identifying investment opportunities in small to mid-cap biotechnology firms that are publicly traded [1]. - There is a particular emphasis on clinical catalysts and earnings related to new drug launches as key areas of interest for investment [1]. Group 2: Analyst's Position - The analyst holds a beneficial long position in the shares of PHVS, indicating a personal investment interest in this specific company [2]. - The article is authored by the analyst without external compensation, reflecting personal opinions rather than institutional views [2]. Group 3: Content Disclaimer - The content provided is for informational and educational purposes only and should not be interpreted as financial or investment advice [3][4]. - The article acknowledges the potential for errors and inaccuracies, emphasizing the importance of conducting due diligence before making investment decisions [3].

Core Viewpoint - Rosen Law Firm is reminding purchasers of MoonLake Immunotherapeutics common stock of the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the class period from March 10, 2024, to September 29, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased MoonLake common stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must move the Court to serve as lead plaintiff by December 15, 2025 [3]. - The lawsuit claims that the defendants made false and misleading statements regarding the clinical benefits of their product SLK compared to traditional monoclonal antibodies, which led to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

MLTX DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 29, 2025 10:14 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 29, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclu ...

Immunovant, Inc. (NASDAQ:IMVT) ranks among the best short squeeze stocks to buy right now. Following the company’s fiscal second-quarter 2026 financial results, Oppenheimer reaffirmed its Outperform rating on Immunovant, Inc. (NASDAQ:IMVT) on November 11 with a price target of $54. The company’s reported earnings per share of -$0.73 fell short of the -$0.71 consensus estimate. With $4.4 billion in cash and no debt on its balance sheet, Immunovant, Inc. (NASDAQ:IMVT) maintains a strong capital position in d ...

NEW YORK, NEW YORK - OCTOBER 08: Traders work on the floor of the New York Stock Exchange during morning trading on October 08, 2024 in New York City. Stocks opened up on the rise after the Dow Jones saw a loss of 400 points amid a rise in oil prices. (Photo by Michael M. Santiago/Getty Images)Getty ImagesEver Wonder How the Market Keeps Rallying While Sectors Rotate In and Out of Favor?Ever wonder how the market keeps rallying while sectors rotate in and out of favor? Over decades of trading since the 1990 ...